2022
Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital
Costa C., Scozzari G., Migliore E., Galassi C., Ciccone G., Ricciardelli G., Scarmozzino A., Angelone A., Cassoni P., Cavallo R.
Vaccines 2022, 10, 1031.
Contributo della Fondazione riconosciuto in “Aknowledgements” a pag. 14
2021
Molecular dynamics of targeting CD38 in multiple myeloma.
Malavasi F, Faini AC, Morandi F, Castella B, Incarnato D, Oliviero S, Horenstein AL, Massaia M, van de Donk NWCJ, Richardson PG.
British Journal Haematology 2021 Feb 11. doi: 10.1111/bjh.17329. Online ahead of print.PMID: 33570193 (I.F. 5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Comparison of CD38 antibodies in vitro and ex vitro mechanisms of action in multiple myeloma.
Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, Rusbuldt J, Bellew K, Kane C, Van de Donk NWC
Haematology. 2021 Jan 14. doi: 10.3324/haematol.2020.268656. Online ahead of print.PMID: 33440920 (I.F. 5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione
PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression.
Costa F, Marchica V, Storti P, Malavasi F, Giuliani N.
Cancers (Basel). 2021 Jan 6;13(2):164. doi: 10.3390/cancers13020164.PMID: 33418913 (I.F. 6.126)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Daratumumab in the treatment of light chain (AL) amyloidosis
Giovanni Palladini, Paolo Milani, F. Malavasi, Gianpaolo Merlini
Cells (2021, in press) (I.F. 4.829)
Contributo della Fondazione Ricerca Molinette: Affiliazione
The key role of NAD+ in anti-tumor immune response: an update
Fabio Morandi, Alberto Leonardo Horenstein, F. Malavasi
Frontiers in Immunology Manuscript ID: 658263 (2021, in press) (I.F. 5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione
The glycolitic pathway as a target for novel onco-immunology therapies in pancreatic cancer.
Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F.
Molecules, 2021, 26(6), 1642. ;
IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions.
Mucciolo G, Curcio C, Roux C, Novelli F. et al.
PNAS 2021 Feb 9;118(6):e2020395118. doi: 10.1073/pnas.2020395118.
2020
In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.
Mandili G, Curcio C, Bulfamante S, Novelli F. et al.
Journal for ImmunoTherapy of Cancer 2020;0:e001071. doi:10.1136/jitc-2020-001071
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients.
Mandili G, Follia L, Ferrero G, Novelli F. et al.
Cancers (Basel) 2020 Mar 21;12(3):746. doi: 10.3390/cancers12030746.
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.
Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.PMID: 33322499 (I.F. 4.829)
Contributo della Fondazione Ricerca Molinette: Affiliazione
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O, Belisario DC, Compagno M, Giovinazzo F, Bracci C, Pastorino U, Horenstein A, Malavasi F, Ferracini R, Scala S, Sozzi G, Roz L, Roato I, Bertolini G.
Frontiers in Immunology 2020 Oct 2;11:02168. doi: 10.3389/fimmu.2020.02168. eCollection 2020.PMID: 33123122 (I.F. 5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione
The Circular Life of Human CD38: From Basic Science to Clinics and Back.
Horenstein AL, Faini AC, Morandi F, Bracci C, Lanza F, Giuliani N, Paulus A, Malavasi F.
Molecules. 2020 Oct 21;25(20):4844. doi: 10.3390/molecules25204844.PMID: 33096610 (I.F.3.267)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH.
Journal Immunotherapy Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987.PMID: 32847986 (I.F. 10.252)
Contributo della Fondazione Ricerca Molinette
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S.
International Journal Molecular Science. 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129.PMID: 32531894 (I.F.4.556)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A.
Blood Advances 2020 May 26;4(10):2143-2157. doi: 10.1182/bloodadvances.2019001091.PMID: 32421811 (I.F. 4.910)
Contributo della Fondazione Ricerca Molinette
The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.
Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, Krishfield S, Malavasi F, Yoon J, Sui SJH, Kyttaris VC, Tsokos GC.
Cell Reports 2020 Jan 7;30(1):112-123.e4. doi: 10.1016/j.celrep.2019.12.014.PMID: 31914379 (I.F.8.109)
Contributo della Fondazione Ricerca Molinette
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, Jachetti E, Ribaldone DG, Caviglia GP, Pastorelli L, De Andrea M, Naviglio S, Lucafò M, Stocco G, Grolla AA, Campolo M, Casili G, Cuzzocrea S, Esposito E, Malavasi F, Genazzani AA, Porta C, Travelli C.
Journal Molecular Medicine (Berl). 2020 Apr;98(4):595-612. doi: 10.1007/s00109-020-01892-0. Epub 2020 Apr 27.PMID: 32338310 (I.F. 4.938)
Contributo della Fondazione Ricerca Molinette
CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy.
Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N.
British Journal of Haematology 2020 Aug;190(3):430-436. doi: 10.1111/bjh.16548. Epub 2020 Mar 12.PMID: 32162328 (I.F.5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.
Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F.
Cancers (Basel). 2020 Jan 28;12(2):303. doi: 10.3390/cancers12020303.PMID: 32012891 (I.F.6.126)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Viral arthritis and COVID-19.
Parisi S, Borrelli R, Bianchi S, Fusaro E.
Lancet Rheumatol. 2020 Nov;2(11):e655-e657. doi: 10.1016/S2665-9913(20)30348-9. Epub 2020 Oct 5. PMID: 33043303 Free PMC article. No abstract available.
Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC, Parisi S, Priora M, Sanna S, Peroni CL, Laganà A, D’Avolio A, Fusaro E.
Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0. PMID: 32999362 Free PMC article.
Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement.
Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L.
Cells. 2020 Sep 16;9(9):2106. doi: 10.3390/cells9092106. PMID: 32947843 Free PMC article.
Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
Ditto MC, Parisi S, Varisco V, Talotta R, Batticciotto A, Antivalle M, Gerardi MC, Agosti M, Borrelli R, Fusaro E, Sarzi-Puttini P.
Clin Exp Rheumatol. 2020 Sep 16. Online ahead of print. PMID: 32940216
Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.
Carnevale A, Silva M, Maietti E, Milanese G, Saracco M, Parisi S, Bravi E, De Gennaro F, Arrigoni E, Bodini FC, Fusaro E, Scirè CA, Sverzellati N, Ariani A.
Clin Rheumatol. 2020 Sep 3. doi: 10.1007/s10067-020-05375-y. Online ahead of print. PMID: 32880053
Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP.
Scand J Rheumatol. 2020 Nov;49(6):505-506. doi: 10.1080/03009742.2020.1800083. Epub 2020 Aug 28. PMID: 32856492 No abstract available.
Rheumatic manifestations in inflammatory bowel disease.
Finucci A, Ditto MC, Parisi S, Borrelli R, Priora M, Realmuto C, Fusaro E.
Minerva Gastroenterol Dietol. 2020 Jul 3. doi: 10.23736/S1121-421X.20.02726-9. Online ahead of print. PMID: 32623869
How to manage rheumatic patients during the coronavirus pandemic.
Parisi S, Ditto MC, Finucci A, Fusaro E.
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28. PMID: 32343511 Free article. No abstract available.
Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents.
Priora M, Realmuto C, Parisi S, Ditto MC, Borrelli R, Peroni CL, Laganà A, Fusaro E. Minerva Gastroenterol Dietol. 2020 Sep;66(3):280-289. doi: 10.23736/S1121-421X.20.02680-X. Epub 2020 Mar 24. PMID: 32218427
LIGHT/TNFSF14 promotes osteolytic bone metastasis in non-small cell lung cancer patients.
G. Brunetti, DC Belisario, S. Bortolotti, G. Storlino, G. Colaianni,
MF Faienza, L. Sanesi, V. Alliod, L. Buffoni, E. Centini, C. Voena, R.
Pulito, S. Novello, G. Ingravallo, R. Rizzi, G. Mori, JE Reseland, CF
Ware, S. Colucci, R. Ferracini , M. Grano, I. Roato.
J Bone Miner Res. 2020; 35(4):671-680.
LIGHT as regulator of bone homeostasis during osteolytic bone metastasis formation in non-small cell lung cancer patients
G. Brunetti, D.C. Belisario, G. Storlino, G. Colaianni, L. Buffoni, G. Ingravallo, C. F. Ware, S. Colucci, R. Ferracini, M. Grano, I. Roato.
Bone Reports 2020;13:100656.
A Novel Method to Optimize Autologous Adipose Tissue Recovery with Extracellular Matrix Preservation.
Roato, F. Mussano, S. Reano, F. Boriani, A. Margara, R. Ferracini, E. Adriani, O. Sabry, M. Fiorini and P. Fattori.
Processes, 2020;8(1):88.
CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells.
O. Fortunato, C.D. Belisario, M. Compagno, F. Giovinazzo, C. Bracci, U. Pastorino, A. L. Horenstein, F. Malavasi, R. Ferracini, S. Scala, G. Sozzi, L. Roz, I. Roato, G. Bertolini
Front Immunol. 2020;11:02168.
2019
Is the adipose-derived mesenchymal stem cell therapy effective for treatment of knee osteoarthritis?
I. Roato, R. Ferracini
Ann. Transl. Med. 2019;7(suppl 3): S114.
The crosstalk between osteodifferentiating stem cells and endothelial cells promotes angiogenesis and bone formation.
T. Genova, S. Petrillo, E. Zicola, I. Roato, R. Ferracini, E. Tolosano, F. Altruda
Front Physiol 2019;10;1291.
Immunotherapy in multiple myeloma: accelerating on the path to the patient.
I. Ghobrial , C. Hernández Cruz , A. Garfall , N. Shah, N. Munshi, J.
Kaufman L. H. Boise, G. Morgan, V. Adalsteinsson, S. Manier, R. Pillar,
F. Malavasi and S. Lonial
Clinical Lymphoma, Myeloma and Leukemia Jun;19(6):332-344 2019 (I.F. 2.308)
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma.
Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH.
Frontiers in Immunology 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. eCollection 2019.PMID: 31552039 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette
Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N, Malavasi F.
Frontiers in Immunology 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.PMID: 31475006 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Novel targets for the treatment of relapsing multiple myeloma.
Giuliani N, Accardi F, Marchica V, Dalla Palma B, Storti P, Toscani D, Vicario E, Malavasi F.
Expert Review in Hematology 2019 Jul;12(7):481-496. doi: 10.1080/17474086.2019.1624158. Epub 2019 Jun 3.PMID: 31125526 Review. (I.F. 2.07)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.
Morandi F, Marimpietri D, Horenstein AL, Corrias MV, Malavasi F.
Oncoimmunology. 2019 Feb 19;8(5):e1574198. doi: 10.1080/2162402X.2019.1574198. eCollection 2019.PMID: 31069133 (I.F. 5.503)
Contributo della Fondazione Ricerca Molinette: Affiliazione
CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Horenstein AL, Bracci C, Morandi F, Malavasi F.
Frontiers in Immunology 2019 Apr 24;10:760. doi: 10.3389/fimmu.2019.00760. eCollection 2019.PMID: 31068926 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.
Clinical Lymphoma, Myeloma and Leukemia 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20.PMID: 31023594 Review. (I.F. 2.02)
Contributo della Fondazione Ricerca Molinette
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A.
Clinical Cancer Research 2019 Jul 1;25(13):3974-3985. doi: 10.1158/1078-0432.CCR-18-3412. Epub 2019 Apr 2.PMID: 30940652 (I.F. 8.9)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy.
Malavasi F, Faini AC.
Clinical Cancer Research 2019 May 15;25(10):2946-2948. doi: 10.1158/1078-0432.CCR-19-0260. Epub 2019 Mar 7.PMID: 30846477 (I.F. 8.9)
Contributo della Fondazione Ricerca Molinette: Affiliazione
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.
Follia L, Ferrero G, Mandili G, Novelli F. et al.
Front. Oncol., 27 February 2019 | https://doi.org/10.3389/fonc.2019.00115
2018
CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells.
I. Schiavoni, C. Scagnolari, AL. Horenstein, P. Leone, A: Pierangeli, F. Malavasi, CM Ausiello and G. Fedele
Immunology: 154(1):122-131, 2018 May (I.F. 4.078)
CD38 antibodies in multiple myeloma: back to the future.
N.W.C.J. van de Donk, P.G. Richardson and F. Malavasi
Blood 4; 131(1):13-29, 2018 (I.F.13.164)
Cytokine-induced killer cells express CD39, CD38, CD203a, CD73 ectoenzymes and P1 adenosinergic receptors.
A.L. Horenstein, A. Chillemi, G. Mesiano, R. Zini, V. Quarona, N.
Bianchi, M. Aglietta, G. Grignani, R. Manfredini, R. Gambari, D.
Sangiolo, F. Malavasi and D. Ferrari
Frontiers in Pharmacology 9:196, Aprile 2018 (I.F. 6.429)
The role of extracellular adenosine generation in the development of autoimmune diseases.
F. Morandi, A.L. Horenstein, R. Rizzo and F. Malavasi
Mediators of Inflammation 7019398, 2018 (I.F. 3.232)
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+.
F. Morandi, D. Marimpietri, A.L. Horenstein, M. Bolzoni, D. Toscani,
F. Costa, B. Castella, A.C. Faini, M. Massaia, V. Pistoia, N. Giuliani
and F. Malavasi
OncoImmunology 7;7(8):e1458809, Maggio 2018 (I.F. 5.503)
A phylogenetic view of the leukocyte ectonucleotidases.
E. Ferrero, A.C. Faini and F. Malavasi
Immunology Letters, 2018 Review (I.F. 2.436)
CD38: a target for immunotherapeutic approaches in multiple myeloma
F. Morandi, A.L. Horenstein, F. Costa, N. Giuliani, V. Pistoia and F. Malavasi
Frontiers in Immunology 28;9:2722, 2018 (I.F. 6.429)
Functional Insights into Nucleotide-Metabolizing Ectoenzymes Expressed by Bone Marrow-Resident Cells in Patients with Multiple Myeloma.
A.L. Horenstein, F. Morandi, C. Bracci, V. Pistoia and F. Malavasi
Immunology Letters 2018 Nov 14 (I.F. 2.436)
Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations.
Morandi F, Horenstein AL, Quarona V, Faini AC, Castella B, Srinivasan RC, Strom SC, Malavasi F, Gramignoli R.
Journal of Immunology 2019 Feb 1;202(3):724-735. doi: 10.4049/jimmunol.1800432. Epub 2018 Dec 26.PMID: 30587530 (I.F. 4.718)
Contributo della Fondazione Ricerca Molinette
I. Roato, D.C. Belisario, Compagno M, Verderio L, Sighinolfi A, Mussano F, Genova T, Veneziano F, Pertici G, Perale G, Ferracini R.
Adipose-Derived Stromal Vascular Fraction/Xenohybrid Bone Scaffold: an Alternative Source for Bone Regeneration.
Stem Cells Intl. 2018;Apr 29;4126379. Epub.
Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners.
Cappello P, Curcio C, Mandili G, Novelli F. et al.
Cancers (Basel) 2018 Feb 16;10(2):51. doi: 10.3390/cancers10020051.
È Soluble stroma-related biomarkers of pancreatic cancer.
Resovi A, Bani MR, Porcu L, Novelli F. et al.
EMBO Mol Med. 2018 Aug;10(8). pii: e8741. doi: 10.15252/emmm.201708741. PubMed PMID: 29941541; PubMed Central PMCID: PMC6079536.
2017
Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.
Borgoni S, Iannello A, Cutrupi S, Allavena P, D’Incalci M, Novelli F, Cappello P.
Oncoimmunology. 2017 Nov 13;7(2):e1393596. doi: 10.1080/2162402X.2017.1393596. eCollection 2018.PMID: 29308326
Endogenous glutamine decrease is associated with pancreatic cancer progression.
Roux C, Riganti C, Borgogno SF, Curto R, Curcio C, Catanzaro V,
Digilio G, Padovan S, Puccinelli MP, Isabello M, Aime S, Cappello P, Novelli F.
Oncotarget. 2017 Aug 24;8(56):95361-95376. doi: 10.18632/oncotarget.20545. eCollection 2017 Nov 10. PMID: 29221133
FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.
Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM,
Roux C, Curcio C, Evangelista A, Allavena P, Salvia R, Rusev B, Scarpa
A, Cappello P, Novelli F.
Oncogene. 2018 Feb 8;37(6):697-709. doi: 10.1038/onc.2017.358. Epub 2017 Oct 23. PMID: 29059164
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
Principe M., Borgoni S., Cascione M., Chattaragada MS., Ferri-Borgogno S., Capello M., Bulfamante S., Chapelle J., Di Modugno F., Defilippi P., Nisticò P., Cappello P., Riganti C., Leporatti S. Novelli F.
J Hematol Oncol. 2017 Jan 13;10(1):16. doi: 10.1186/s13045-016-0385-8. PMID: 28086938
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.
Griggio V., Mandili G., Vitale C., Capello M., Macor P., Serra S., Castella B., Peola S., Foglietta M., Drandi D., Omedé P., Sblattero D., Cappello P., Chiarle R., Deaglio S., Boccadoro M., Novelli F., Massaia M., Coscia M.
Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712. PMID: 27906678
Alpha-Enolase (ENO1), a potential target in novel immunotherapies.
Cappello P., Principe M., Bulfamante S., Novelli F.
Front Biosci (Landmark Ed). 2017 Jan 1;22:944-959. doi: 10.2741/4526.
PMID: 27814656
Bone Metastasis from Solid Tumors: Biologic and Clinical State of the Art.
I. Roato, A. Massè, R. Piana, R. Ferracini.
Clin Rev Bone Miner Metab 2017;15:115-122.
2016
Adipose Derived-Mesenchymal Stem Cells Viability and Differentiating Features for Orthopaedic Reparative Applications: Banking of Adipose Tissue.
I. Roato, D. Alotto, D.C. Belisario, S. Casarin, M. Fumagalli, I. Cambieri, R. Piana, M. Stella, R. Ferracini, C. Castagnoli.
Stem Cells Int. 2016;2016:4968724.Epub.
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.
L. D’Amico, C.D. Belisario, G. Migliardi, C. Grange, B. Bussolati, P.
D’Amelio, T. Perera, E. Dalmasso, L. Dalle Carbonare, L. Godio, P.M.
Comoglio, L. Trusolino, R. Ferracini, I. Roato.
Oncotarget. 2016;7(29):45525-45537.
Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response.
Cappello P., Tonoli E., Curto R., Giordano D., Giovarelli M., Novelli F.
Oncoimmunology. 2015 Dec 21;5(5):e1112940. doi: 10.1080/2162402X.2015.1112940. eCollection 2016 May. PMID: 27467915
Regulation of Langerhans cell functions in a hypoxic environment.
Pierobon D., Raggi F., Cambieri I., Pelassa S., Occhipinti S., Cappello P., Novelli F., Musso T., Eva A., Castagnoli C., Varesio L., Giovarelli M., Bosco MC.
J Mol Med (Berl). 2016 Aug;94(8):943-55. doi: 10.1007/s00109-016-1400-9. Epub 2016 Mar 10. PMID: 26960761
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.
Capello M., Ferri-Borgogno S., Riganti C., Chattaragada MS., Principe M., Roux C., Zhou W., Petricoin EF., Cappello P,. Novelli F.
Oncotarget. 2016 Feb 2;7(5):5598-612. doi: 10.18632/oncotarget.6798. PMID: 26734996
2015
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
Principe M., Ceruti P., Shih NY., Chattaragada MS., Rolla S., Conti L., Bestagno M., Zentilin L., Yang SH., Migliorini P., Cappello P., Burrone O., Novelli F.
Oncotarget. 2015 May 10;6(13):11098-113. doi: 10.18632/oncotarget.3572.
PMID: 25860938
2014
Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, Amici A, Cavallo F, Cappello P, Pierobon D, Novelli F, Giovarelli M.
Clin Cancer Res. 2014 Jun 1;20(11):2910-21. doi: 10.1158/1078-0432.CCR-13-2663. Epub 2014 Mar 25. PMID: 24668647